Pseudomonas Aeruginosa Infection is caused by a bacterium from the genus Pseudomonas. It is an aerobic gram-negative bacterium and is characterized by motile, non-spore-forming rods that are oxidase-positive and lactose non-fermenters. This bacteria is commonly found in the environment, like in soil and water. Infection caused by P. aeruginosa is common, with the burden of infection in hospitalized patients.
P. aeruginosa is intrinsically resistant to the majority of antimicrobial agents due to its selective ability to prevent various antibiotic molecules from penetrating its outer membrane or to extrude them if they enter the cell. The antimicrobial groups that remain active include some fluoroquinolones (such as ciprofloxacin and levofloxacin), aminoglycosides (such as gentamicin, tobramycin, and amikacin), some beta-lactams (such as piperacillin-tazobactam, ceftazidime, cefepime, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem, meropenem, doripenem), and polymyxins.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/pseudomonas-aeruginosa-infection-market
The Pseudomonas Aeruginosa Infection Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Pseudomonas Aeruginosa Infection market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Pseudomonas Aeruginosa Infection treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pseudomonas Aeruginosa Infection Market Key Facts
-
The National Nosocomial Infections Surveillance System (NNIS) reports P. aeruginosa to be the second most common organism isolated in nosocomial pneumonia, the third most common organism isolated in both urinary tract infection (UTI) and surgical site infection, and the fifth most common organism isolated from all sites of nosocomial infection.
-
As per the Centers for Disease Control and Prevention (CDC), there are an estimated 51,000 healthcare-associated pseudomonas aeruginosa infections cases that occur each year in the United States. Also, in 2017, multidrug-resistant P. aeruginosa caused an estimated 32,600 infections among hospitalized patients in the United States.
-
The data by Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (2017) reported that the annual incidence rate of Pseudomonas aeruginosa infections among MHS beneficiaries treated at a military treatment facility (MTF) was found to be approximately 30.6 per 100,000 persons per year.
Key Benefits of Pseudomonas Aeruginosa Infection Market Report
-
Pseudomonas Aeruginosa Infection market report provides an in-depth analysis of Pseudomonas Aeruginosa Infection Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Pseudomonas Aeruginosa Infection Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Pseudomonas Aeruginosa Infection current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Pseudomonas Aeruginosa Infection market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Pseudomonas Aeruginosa Infection Market
The Pseudomonas Aeruginosa Infection market size is expected to experience positive growth in the coming years, owing to the already prescribed products along with the launch of emerging therapies. The key driver for the surge in market size is the rise in the number of incident cases for antibiotic-resistant infections, increase in the R&D activities and the emergence of multi-drug resistant pathogens along with the burden of antibiotic-resistant infections.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pseudomonas Aeruginosa Infection market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Pseudomonas Aeruginosa Infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Pseudomonas Aeruginosa Infection Epidemiology
The epidemiology section covers insights about the historical and current Pseudomonas Aeruginosa Infection patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Pseudomonas Aeruginosa Infection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pseudomonas Aeruginosa Infection market or expected to get launched in the market during the study period. The analysis covers Pseudomonas Aeruginosa Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Pseudomonas Aeruginosa Infection Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Pseudomonas Aeruginosa Infection market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Pseudomonas Aeruginosa Infection emerging therapies.
Request for Sample @ Pseudomonas Aeruginosa Infection Therapeutics Market Assessment
The dynamics of the Pseudomonas Aeruginosa Infection market is anticipated to change in the coming years, owing to the increase in the initiatives toward control of drug resistance, the emergence of multi-drug resistance pathogens, and also expects the launch of emerging therapies during the forecast period.
Pseudomonas Aeruginosa Infection Companies:
-
Antabio
-
Venatorx
-
Shionogi
-
Spero Pharmaceuticals
-
Armata Pharmaceuticals
And others
Pseudomonas Aeruginosa Infection Therapies covered in the report include:
-
SPR994
-
AP-PA02
-
Cefepime-tanibo rbactam(formerly VNRX-5133)
And many others.
The pipeline of the Pseudomonas Aeruginosa Infection is mainly focused on the treatment of drugs resistance infections The current scenario also anticipates a positive shift in the market for the forecast period.
Table of Content
1. Key Insights
2. Executive Summary
3. Pseudomonas Aeruginosa Infection Competitive Intelligence Analysis
4. Pseudomonas Aeruginosa Infection Market Overview at a Glance
5. Pseudomonas Aeruginosa Infection Disease Background and Overview
6. Pseudomonas Aeruginosa Infection Patient Journey
7. Pseudomonas Aeruginosa Infection Epidemiology and Patient Population
8. Pseudomonas Aeruginosa Infection Treatment Algorithm, Current Treatment, and Medical Practices
9. Pseudomonas Aeruginosa Infection Unmet Needs
10. Key Endpoints of Pseudomonas Aeruginosa Infection Treatment
11. Pseudomonas Aeruginosa Infection Marketed Products
12. Pseudomonas Aeruginosa Infection Emerging Therapies
13. Pseudomonas Aeruginosa Infection Seven Major Market Analysis
14. Attribute Analysis
15. Pseudomonas Aeruginosa Infection Market Outlook (7 major markets)
16. Pseudomonas Aeruginosa Infection Access and Reimbursement Overview
17. KOL Views on the Pseudomonas Aeruginosa Infection Market.
18. Pseudomonas Aeruginosa Infection Market Drivers
19. Pseudomonas Aeruginosa Infection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/pseudomonas-aeruginosa-infection-market
Latest Reports By DelveInsight
Pseudomonas Aeruginosa Infection Pipeline Insight
Pseudomonas Aeruginosa Infection Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Pseudomonas Aeruginosa Infection Market.
DelveInsight’s “Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/